Emerging drugs for head and neck cancer

Bibliography

• JEMAL A, MURRAY T, SAMUELS A, GHAFOOR A, WARD E, THUN MJ: Cancer statistics, 2003. CA Cancer. J. (2003) 53(1):5–26.
   PubMed Web of Science ®Google Scholar
• VOKES EE, WEICHSELBAUM RR, LIPPMAN SM, HONG WK: Head and neck cancer. N Eng1.1. Med. (1993) 328(3):184–194.
   Google Scholar
• ••A comprehensive and illustrated review ofhead and neck cancer.
   Google Scholar
• PIGNON JP, BOURHIS J, DOMENGE C, DESIGNE L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet (2000) 355(9208)949–955.
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis including 63 randomisedtrials (> 10,000 patients) demonstrating only a 4% absolute survival benefit of chemotherapy, in addition to local treatment.
   Google Scholar
• VOGL SE, SCHOENFELD DA, KAPLAN BH, LERNER HJ, ENGSTROM PF, HORTON J: A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin and cisplatin in head and neck cancer. Cancer (1985) 56(3):432–442.
   PubMed Web of Science ®Google Scholar
• FORASTIERE AA, METCH B, SCHULLER DE et al.: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. I Cirri. Oncol (1992) 10(8):1245–1251.
   PubMed Web of Science ®Google Scholar
• •Southwest Oncology Group study showed that combination chemotherapy with a platinum analogue plus 5-FU resulted in a higher response rate than single-agent MTX, but no improvement in survival.
   Google Scholar
• EISENBERGER M, KRASNOW S, ELLENBERG S et al.: A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer.Oncol (1989) 7(9):1341–1345.
   Google Scholar
• HONG WK, SCHAEFER S, ISSELL B et al.: A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer (1983) 52(2):206–210.
   PubMed Web of Science ®Google Scholar
• VERMORKEN JB, CATIMEL G, HOEKMAN K et al.: Randomized Phase II trial of methotrexate versus two schedules of paclitaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc. Am. Soc. Cirri. Oncol (1998) 17:391a.
   Google Scholar
• DECONTI RC, SCHOENFELD D: A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer (1981) 48(5):1061–1072.
   PubMed Web of Science ®Google Scholar
• TAYLOR SG IV, MCGUIRE WP, HAUCK WW, SHOWEL JL, LAD TE: A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J. Clin. Oncol (1984) 2(9):1006–1011.
   PubMed Web of Science ®Google Scholar
• HITT R, PAZ-ARES L, HIDALGO M et al.: Phase I/II study of paclitaxelkisplatin as first-line therapy for locally advanced head and neck cancer. Semia Oncol (1997) 24(6, Suppl. 19):519–524.
   Google Scholar
• FORASTIERE AA, LEONG T, ROWINSKY E et al: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group study E1393. I Clin. Oncol (2001) 19(4):1088–1095.
   Web of Science ®Google Scholar
• JACOBS C, LYMAN G,VELEZ-GARCIA E et al.: A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. amyl (1992) 10(2):257–263.
   Web of Science ®Google Scholar
• •Phase III study that showed which although response rate was improved with the combination of cisplatin and 5-FU as compared with single agents, survival was not improved.
   Google Scholar
• VERONESI A, ZAGONEL V, TIRELLI U et al.: High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J. Clin. amyl (1985) 3(8):1105–1108.
   Web of Science ®Google Scholar
• HAVLIN KA, KUHN JG, MYERS JW et al.: High-dose cisplatin for locally advanced or metastatic head and neck cancer. A Phase II pilot study. Cancer (1989); 63(3):423–427.
   PubMed Web of Science ®Google Scholar
• FORASTIERE AA, SHANK D, NEUBERG D, TAYLOY SG IV, DECONTI RC, ADAMS G: Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer (1998) 82(10:2270–2274.
   PubMed Web of Science ®Google Scholar
• COLEVAS AD, POSNER MR: Docetaxel in head and neck cancer: a review. Am. J. Oncol (1998) 21(5):482–486.
   PubMed Web of Science ®Google Scholar
• HUBER MH, LIPPMAN SM, BENNER SE et al: A Phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am. J. Clin. amyl (1996) 19(4):379–382.
   Web of Science ®Google Scholar
• BUESA JM, FERNANDEZ R, ESTEBAN E et al: Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann. Oncol (1991) 2(2):151–152.
   PubMed Web of Science ®Google Scholar
• CERVELLINO JC, ARAUJO CE, PIRISI C, FRANCIA A, CERRUTI R: Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study. Oncology (1991) 48(2):89–92.
   PubMed Web of Science ®Google Scholar
• SANDLER A, SAXMAN S, BANDEALY M et al.: Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial. Am. J. Clin. Oncol (1998) 21(2):195–197.
   PubMed Web of Science ®Google Scholar
• EISENBERGER M, HORNEDO J, SILVA H, DONEHOWER R, SPAULDING M, VAN ECHO D: Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol (1986) 4(10):1506–1509.
   PubMed Web of Science ®Google Scholar
• VOLLING P, SCHRODER M, RAUSCHNING W, ACHTERRATH W, STENNERT E: Carboplatin. The better platinum in head and neck cancer? Arch. Otolaryngol Head Neck Surg. (1989) 115(6):695–698.
   PubMed Web of Science ®Google Scholar
• SHIN DM, LIPPMAN SM: Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. Schuh. amyl (1999) 26(1, Suppl. 2):100–105.
   Google Scholar
• •Taxanes emerge as among the most active single agents in HNSCC.
   Google Scholar
• VOGL SE, SCHOENFELD DA, KAPLAN BH, LERNER HJ, ENGSTROM PE HORTON J: A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer (1985) 56(3):432–442.
   PubMed Web of Science ®Google Scholar
• MURPHY B, LI Y, CELLA D et al: Phase II study comparing cisplatin 5-fluorouracil versus cisplatin paclitaxel in metastatic/recurrent head neck cancer. Proc. Am. Soc. Clin. Oncol (2001) 20:224a.
   Google Scholar
• HITT R, PAZ-ARES L, HIDALGO M et al.: Phase I/II study of paclitaxelkisplatin as first-line therapy for locally advanced head and neck cancer. Semi]. Oncol (1997) 24:S19–S24.
   Google Scholar
• FORASTIERE AA, LEONG T, ROWINSKY E et al.: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group study E1393. I Clin. Oncol (2001) 19:1088–1095.
   Web of Science ®Google Scholar
• SHIN DM, GLISSON BS, KHURI FR et al: Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma../. Oncol (1998) 16(4):1325–1330.
   Google Scholar
• SHIN DM, KHURI FR, GLISSON BS et al.: Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer (2001) 91(7):1316–1323.
   PubMed Web of Science ®Google Scholar
• •The TIC regimen resulted in overall response rates of 59% in metastatic or recurrent disease.
   Google Scholar
• SHIN DM, GLISSON BS, KHURI FR et al.: Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer (2002) 95(2):322–330.
   PubMed Web of Science ®Google Scholar
• •The TIC regimen resulted in overall response rates of 81% in induction setting.
   Google Scholar
• POSNER MR, GLISSON B, FRENETTE G et al: Multicenter Phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. I Clin. Oncol (2001) 19(4):1096–1104.
   Web of Science ®Google Scholar
• •This Phase I - II multi-centre trial showed that induction with docetaxel, cisplatin, and 5-FU resulted in a high major response rate of 93%, including 40% clinical complete response rate. Pathological negative biopsies were confirmed in 92% patients with clinical complete response and 54% patients with partial response or no change.
   Google Scholar
• HITT R, LOPEZ-POUSA A, RODRIGUEZ M et al: Phase III study comparing cisplatin and 5-fluoruracil versus cisplatin, 5-fluorouracil and paclitaxel as induction therapy in locally advanced head and neck. Proc. Am. Soc. Clin. Oncol (2003) 22:496.
   Google Scholar
• SPITZ MR: Epidemiology and risk factors for head and neck cancer. Semi]. Oncol (1994) 21(3):281–288.
   PubMed Web of Science ®Google Scholar
• LEON X, HITT R, CONSTENLA M et al: A retrospective analysis of the outcome of patients with recurrent or metastatic squamous cell carcinoma of the head and neck who are progressing while on a platinum-based palliative chemotherapy. Proc. Am. Soc. Clin. Oncol. (2003) 22:502.
   Google Scholar
• CARPENTER G: Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev Biochem. (1987) 56:881–914.
   PubMed Web of Science ®Google Scholar
• REISS M, STASH EB, VELLUCCI VF, ZHOU ZL: Activation of the autocrine transforming growth factor alpha pathway in human squamous carcinoma cells. Cancer Res. (1991) 51(21, Part 1):6254–6262.
   Google Scholar
• HOFER DR, SHERWOOD ER, BROMBERG WD, MENDELSOHN J, LEE C, KOZLOWSKI JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res. (1991) 51(11):2780–2785.
   PubMed Web of Science ®Google Scholar
• NEAL DE, MARSH C, BENNETT MK et al: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 1(8425):366–368.
   PubMed Web of Science ®Google Scholar
• SAINSBURY JR, MALCOLM AJ, APPLETON DR, FARNDON JR, HARRIS AL: Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. Patna. (1985) 38(11):1225–1228.
   Google Scholar
• WALED, ASHCROFT T, MARSH C, GIBSON GJ, HARRIS AL: Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer (1987) 55(5):513–516.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, TVVEARDY DJ: Elevatedlevels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. (1993) 53(15):3579–3584.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, TWEARDY DJ, MELHEM MF: Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin. Cancer. Res. (1998) 4(1):13–20.
   PubMed Web of Science ®Google Scholar
• SHIN DM, RO JY, HONG WK, HITTELMAN WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. (1994) 54(12):3153–3159.
   PubMed Web of Science ®Google Scholar
• KE LD, ADLER-STORTHZ K, CLAYMAN GL, YUNG AW, CHEN Z: Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck (1998) 20(4):320–327.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, MELHEM MF, BARNES EL, TWEARDY DJ: Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer (1996) 78(6):1284–1292.
   Google Scholar
• HERBST RS, MADDOX AM, ROTHENBERG ML et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial../. Chit. Oncol (2002) 20(18):3815–3825.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, MCKENNA WG, WEBER CN et al.: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. (2002) 8(3):885–892.
   PubMed Web of Science ®Google Scholar
• COHEN EE, ROSEN F, DEKKER A et al: Phase II study of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol (2003) 21(10):1980–1987.
   PubMed Web of Science ®Google Scholar
• •ZD1839 was shown to have single-agent activity in recurrent HNSCC with an acceptable toxicity profile.
   Google Scholar
• COHEN EE, STENSON K, GUSTIN DM et al: A Phase II study of 250-mg gefitinib monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol (2003) 22:502.
   Google Scholar
• INOUE A, SAIJO Y, MAEMONDO M et al.: Severe acute interstitial pneumonia and gefitinib. Lancet (2003) 361(9373):137–139.
   PubMed Web of Science ®Google Scholar
• POLACK VA, SAVAGE DM, BAKER DA et al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinoma with OSI-774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmcol Exp. Ther. (1999) 291(2):739–748.
   PubMed Web of Science ®Google Scholar
• MOYER JD, BARBACCI EG, IWATA KK et al.: Induction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57(20:4838–4848.
   PubMed Web of Science ®Google Scholar
• HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Oncol. (2001) 19(13):3267–3279.
   Web of Science ®Google Scholar
• •OSI-774 was shown to be well-tolerated in the Phase I setting, with several patients with advanced solid malignancies demonstrating either antitumour activity or long periods of stable disease.
   Google Scholar
• FORERO L, PATNAIK A, HAMMOND LA et al: Phase I, pharmacokinetic and biologic study of OSI-774, a selective epidermal growth factor receptor tyrosine kinase inhibitor in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol. (2002) 21:25b.
   Web of Science ®Google Scholar
• SOULIERES D, SENZER NN, VOKES EE, HIDALGO M, AGARWALA SS, SIU LL: Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck../. Clin. Oncol (2004) 22(1):77–85.
   Web of Science ®Google Scholar
• MYERS JN, HOLSINGER FC, BEKELE BN et al.: Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch. Otolaryngol Head Neck Surg. (2002) 128(8):875–879.
   PubMed Web of Science ®Google Scholar
• MURREN JR,PAPADIMITRAKOPOULOU VA, SIZER KC, VAIDYANATHAN S, RAVERA C, ABBRUZZESE J: A Phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Proc. Am. Soc. Clin. Oncol. (2002) 21:95a.
   Web of Science ®Google Scholar
• SHIN DM, NEMUNAITIS J, ZINNER RG et al.: A Phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) 20:82a.
   Google Scholar
• ZINNER RG, NEMUNAITIS J, DONATO NJ et al: A Phase I clinical and biomarker study of CI-1033 in patients with solid tumors. Proc. AACR-NCI-EORTC Int. Corti 2001. (2001) 566 (Abstract).
   Google Scholar
• GARRISON MA, TOLCHER A, MCCREERY H et al: A phase I and pharmacokinetic study of CI-1033, a Pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Proc. Am. Soc. Oncol. (2002) 20:72a.
   Google Scholar
• CIARDIELLO F, DAMIANO V, BIANCO R et al.: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. .1 Nati Cancer Inst. (1996) 88(23):1770–1776.
   PubMed Web of Science ®Google Scholar
• PREWETT M, ROTHMAN M, WAKSAL H, FELDMAN M, BANDER NH, HICKLIN DJ: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin. Cancer Res. (1998) 4(12):2957–2966.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, BIANCO R, DAMIANO V et al.: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. (1999) 5(4):909–916.
   PubMed Web of Science ®Google Scholar
• BASELGA J, PFISTER D, COOPER MR, COHEN R et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.Oncol (2000)18(4):904–914.
   Google Scholar
• SHIN DM, DONATO NJ, PEREZ-SOLER R et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. (2001) 7(5):1204–1213.
   PubMed Web of Science ®Google Scholar
• •This Phase Ib study showed that C225, a monoclonal antibody to EGFR, significantly saturates tumour EGFR by immunohistochemistry studies. The article discusses this novel mechanism of cancer therapy in head and neck cancer and other tumours with high EGFR expression.
   Google Scholar
• KIES MS, ARQUETTE MA, NABELL L et al.: Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncol. (2002) 21:232a.
   Web of Science ®Google Scholar
• BASELGA J, TRIGO JM, BOURHIS J et al.: Cetuximab plus cisplatin/carboplatin is active in patients with recurrent/ metastatic squamous cell carcinoma of the head and neck progressing on a same dose and schedule platinum-based regimen. Proc. Am. Soc. Clin. Oncol. (2002) 21:226a.
   Google Scholar
• BURTNESS BA, LI Y, FLOOD W et al.: Phase III trial comparing cisplatin + placebo to cisplatin + anti-epidermal growth factor antibody C225 in patients with metastatic/ recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:226a.
   Google Scholar
• VEGE-VILLEGAS E, AQADA A, MESIA R et al: A Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. (2003) 22:502.
   Google Scholar
• BONNER J, EZEKIEL M, ROBERT F, MEREDITH R, SPENCER S, WAKSAL H: Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies. Proc. Am. Soc. Clin. Oncol (2000) 19:4a.
   Google Scholar
• PFISTER DG, ALIFF TB, KRAUS DH et al.: Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy for locoregionally advanced, squamous cell head and neck cancer: preliminary evaluation of a new combined-modality paradigm. Proc. Am. Soc. Clin. Oncol (2003) 22:495.
   Google Scholar
• WINQUIST E, NABID A, SICHERI D et al.: A Phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy. Proc. Am. Soc. Clin. Oncol. (2002) 21:232a.
   Web of Science ®Google Scholar
• TEWES M, SCHLEUCHER N, DIRSCH 0 et al.: Results of a Phase I trial of humanized anti epidermal growth factor receptor monoclonal antibody EMD 72000 in patiens with EGFR expressing solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:95a (Abstract 378).
   Web of Science ®Google Scholar
• BIER H, HOFFMAN T, HAUSER U et al.: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72000 in patients with advanced squamous cell carcinoma of the larynx and Hypopharynx. Cancer Chemother. Pharmacol (2001) 47:519–524.
   PubMed Web of Science ®Google Scholar
• SHIN DM, LEE JS, LIPPMAN SM et al: p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. (1996) 88(8):519–529.
   PubMed Web of Science ®Google Scholar
• BOYLE JO, HAKIM J, KOCH W et al: The incidence of p53mutations increases with progression of head and neck cancer. Cancer Res. (1993) 53(19):4477–4480.
   PubMed Web of Science ®Google Scholar
• CABELGUENNE A, BLONS H, DE WAZIERS I et al: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J. Chit. Oncol (2000) 18(7):1465–1473.
   PubMed Web of Science ®Google Scholar
• GANLY I, ECKHARDT SG, RODRIGUEZ, GI et al: A Phase I study of Onyx-015, an EiB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. (2000) 6(3):798–806.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, KHURI F, GANLY I et al.: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. Clin. OncoL (2001) 19(2):289–298.
   Web of Science ®Google Scholar
• HEISE C, SAMPSON-JOHANNES A, WILLIAMS A, MCCORMICK F, VON HOFF DD, KIRN DH: ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. (1997) 3(6):639–645.
   PubMed Web of Science ®Google Scholar
• KHURI FR, NEMUNAITIS J, GANLY I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. (2000) 6(8):879–885.
   PubMed Web of Science ®Google Scholar
• ••This article proposes intratumouralinjection ONYX-015 as an active method for local control in addition to systemic chemotherapy for patients with recurrent head and neck cancer.
   Google Scholar
• RUDIN CM, COHEN EE, PAPADIMIRAKOPOULOU VA et al: An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.Oncol (2003)21:4546–4552.
   Google Scholar
• LIU TJ, ZHANG WW, TAYLOR DL, ROTH JA, GOEPFERT H, CLAYMAN GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. (1994) 54(14):3662–3667.
   PubMed Web of Science ®Google Scholar
• GOODWIN WJ, ESSER D, CLAYMAN GL, NEMUNAITIS J, YVER A, DREILING LK: Randomized Phase II study of intratumoral injection of two dosing schedules using a replication-deficient adenovirus carrying the p53 gene (AD5CMV-P53) in patients with recurrent/ refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol (1999) 18:445a.
   Google Scholar
• CLAYMAN GL, FRANK DK, BRUSO PA, GOEPFERT H: Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. (1999) 5(7):1715–1722.
   PubMed Web of Science ®Google Scholar
• OLD LJ: Tumor necrosis factor. Science (1985) 230:630–632.
   PubMed Web of Science ®Google Scholar
• SENZER N, MANI S, ROSEMURGY A et al: TNF-erade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a Phase I study in patients with solid tumors. ./. Clin. Oncol (2004) 22(4):592–601.
   Web of Science ®Google Scholar
• GLISSON S, HUBER J, GAUGLER M et al: Smokeless tobacco induced oral cavity tumors in Kentucky have a high incidence of hras mutations. Proc. Am. Soc. Clin. Oncol (1998) 17:399a.
   Web of Science ®Google Scholar
• HAHN S, KIEL K, BRIGGS M et al: Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778123 in combination with radiotherapy. Proc. Am. Soc. Clin. Oncol (2000) 19:231a.
   Web of Science ®Google Scholar
• HOLDEN S, ECKHARDT SG, FISHERS et al: A Phase I pharmacokinetic (PK) and biologic study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol (2001) 20:80a.
   Google Scholar
• KIES MS, CLAYMAN GL, EL-NAGGAR AK et al.: Induction therapy with SCH 66336: a farnesyl transferase inhibitor in squamous cell carcinoma (SCC) of the head and neck. Proc. Am. Soc. Clin. Oncol ( 2001) 20:896 (Abstract).
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Clinical applications of research on angiogenesis. N Engl. J. Med. (1995) 333(26):1757–1763.
   PubMed Web of Science ®Google Scholar
• ••This seminar discusses the role ofangiogenesis in neoplastic and non-neoplastic diseases.
   Google Scholar
• DENHART BC, GUIDI AJ, TOGNAZZI K, DVORAK HF, BROWN LF: Vascular permeability factor/ vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab. Invest. (1997) 77(6):659–664.
   PubMed Web of Science ®Google Scholar
• FONG TAT, SHAWVER LK, SUN L et al: 5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59(1):99–106.
   PubMed Web of Science ®Google Scholar
• ROSEN L, MULAY M, MAYERS A et al: Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc. Am. Soc. Chit. Oncol (1999) 18:161a.
   Google Scholar
• ZAHALSKY AJ, WONG RJ, LIS E et al: Phase II trial of SU5416 in patients with advanced incurable head and neck cancer. Proc. Am. Soc. Clin. Oncol (2002) 21:226a.
   Google Scholar
• Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D(2002) 3(1):28–30.
   PubMedGoogle Scholar
• GORDON MS, MARGOLIN K, TALPAZ M et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Clin. Oncol (2001) 19(3):843–850.
   Web of Science ®Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol (2003) 21(1):60–65.
   PubMed Web of Science ®Google Scholar
• OIKAWA T, SASAKI T, NAKAMURA M et al: The proteasome is involved in angiogenesis. Biochem. Biophys. Res. Commun. (1998) 246(1):243–248.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, RICHARDSON P, CHAUHAN D et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 61(7):3071–3076.
   PubMed Web of Science ®Google Scholar
• SHAH SA, POTTER MW, MCDADE TP et al: 26S Proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. I Cell. Biochem. (2001) 82(1):110–122.
   Web of Science ®Google Scholar
• FRANKEL A, MAN S, ELLIOT P, ADAMS J, KERBEL RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer. Res. (2000) 6(9):3719–3728.
   PubMed Web of Science ®Google Scholar
• FAN XM, WONG BC, WANG WP et al: Inhibition of proteasome function induced apoptosis in gastric cancer. Int. J. Cancer (2001) 93(4):481–488.
   PubMed Web of Science ®Google Scholar
• AGHAJANIAN C, SOIGNET S, DIZON DS et al: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. (2002) 8(8):2505–2511.
   PubMed Web of Science ®Google Scholar
• •This article discusses PS-341 as the first drug in its class and the Phase I results in patients with various solid tumours.
   Google Scholar
• RYAN DP, EDER JP, WINKELMANN J et al.: Pharmacokinetic and pharmacodynamic Phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21:95a.
   Web of Science ®Google Scholar
• IQBAL S, LENZ HJ, GROSHEN S et al: Phase I study of PS-341 in combination with 5-FU/LV in solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21:93 (Abstract 370).
   Web of Science ®Google Scholar
• THOMAS JP, ARZOOMANIAN R, ALBERTI D et al.: A Phase I and pharmacodynamic study of the proteosome inhibitor PS-341 in combination with doxorubicin. Proc. Am. Soc. Clin. Oncol (2002) 21:93 (Abstract 368).
   PubMed Web of Science ®Google Scholar
• CLARK JW, RYAN D, DEES C et al: Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21:93 (Abstract 369).
   Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, RICHARDSON PG et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2003) 101(6):2377–2380.
   PubMed Web of Science ®Google Scholar
• LEBOWITZ PF, HARKINS C, CONLEY B et al: Concomitant therapy with proteosome inhibitor, bortezomib and radiation in patients with recurrent or metastatic head and neck squamous cell carcinoma. Proc. Am. Soc. Clin. Oncol (2003) 22:499.
   Web of Science ®Google Scholar
• LIPPMAN SM, BATSAKIS JG, TOTH BB et al.: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinonogenesis. N Engl. I Med. (1993) 328(1):15–20.
   PubMed Web of Science ®Google Scholar
• HONG WK, ENDICOTT J, ITRI LM et al.: 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl. I Med. (1986) 315(24):1501–1505.
   PubMed Web of Science ®Google Scholar
• ••Landmark study in which 13-th-retinoic acid was shown to be effective in oral premalignant lesions.
   Google Scholar
• SHIN DM, RICHARDS TJ, SEIXAS-SILVA JA et al: Phase II trial of bioadjuvant therapy with interferon2a, 13-cis-retinoic acid, and alpha-tocopherol for locally advanced squamous cell carcinoma of the head and neck: long term follow-up. Proc. Am. Soc. Clin. Oncol (2003) 22:496.
   Google Scholar
• SHIBATA J, MURAKAMI K, AOYAGI Y et al.: The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis(trimethylsily0 benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer. Anticancer Res. (2000) 20(5B):3583–3590.
   PubMed Web of Science ®Google Scholar
• RIZVI NA, MARSHALL JL, NESS E et al: Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. Clin. Oncol (2002) 20(16):3522–3532.
   Web of Science ®Google Scholar
• DUVIC M, HYMES K, HEALD P et al: Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T-cell lymphoma: multinational Phase II-III trial results. Clin. Oncol (2001) 19(9):2456–2471.
   Web of Science ®Google Scholar
• SONG JI, LANGO MN, HWANG JD et al.: Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res. (2001) 61(15):5919–5925.
   PubMed Web of Science ®Google Scholar
• RIZVI NA, MARSHALL JL, DAHUT W et al: A Phase I study of LGD1069 in adults with advanced cancer. Clin. Cancer Res. (1999) 5(7):1658–1664.
   PubMed Web of Science ®Google Scholar
• PAPADIMITRAKOPOULOU V, KHURI FR, LIPPMAN SM et al: Phase I/ II evaluation of Targretin (LDG1069), a novel, RXR-specific retinoid, in patients with recurrent squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol (1998) 17:392a.
   Google Scholar
• LIN DT, SUBBARAMAIAH K, SHAH JP, DANNENBERG AJ, BOYLE JO: Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck (2002) 24(8):792–799.
   PubMed Web of Science ®Google Scholar
• MASFERRER JL, LEAHY KM, KOKI AT et al.: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. (2000) 60(5):1306–1311.
   PubMed Web of Science ®Google Scholar
• MESTRE JR, CHAN G, ZHANG F et al: Inhibition of cyclooxygenase-2 expression: an approach to preventing head and neck cancer. Ann. NY Acad. Sci. (1999) 889:62–71.
   PubMed Web of Science ®Google Scholar
• BRESALIER RS: Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis. Gastroenterology (2000)119(6):1797–1798.
   PubMedGoogle Scholar
• REDDY BS, HIROSE Y, LUBET R et al: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. (2000) 60(2):293–297.
   PubMed Web of Science ®Google Scholar
• REDDY BS, RAO CV: Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs. Drugs Aging (2000) 16(5):329–334.
   PubMed Web of Science ®Google Scholar
• DAVIES G, MARTIN LA, SACKS N, DOWSETT M: Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann. Oncol (2002) 13(5):669–678.
   PubMed Web of Science ®Google Scholar
• BADAWI AF, BADR MZ: Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. mnt..j Oncol (2002) 20(6):1109–1122.
   PubMed Web of Science ®Google Scholar
• HU KQ: Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J. Lab. Clin. Med. (2002) 139(4):234–243.
   PubMed Web of Science ®Google Scholar
• PATTON SE, HALL MC, OZEN H: Bladder cancer. Corr. Opin. Oncoi (2002)14(3):265–272.
   PubMed Web of Science ®Google Scholar
• WANG Z, FUENTES CF, SHAPSHAY SM: Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope (2002) 112(5):839–843.
   PubMed Web of Science ®Google Scholar
• CHEN Z, ZHANG X, WANG Z et al: A possible interaction between epidermal growth factor receptor and cyclooxygenase-2 mediated pathways in squamous cell carcinoma of the head and neck. Proc. Am. Assoc. Cancer Res. (2003) 44:510a.
   Google Scholar
• SHIN DM, WANG ZQ, ZHANG X et al: ZD1839, an epidermal growth factor receptor tyrosine inhibitor, inhibits cell growth synergistically with a cyclooxygenase-2 inhibitor, celecoxib, in squamous cell carcinoma of the head and neck. Proc. Am. Assoc. Cancer Res. (2003) 44:1084a.
   Google Scholar